Live Markets
Tuesday, July 28, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Vivos Therapeutics, Inc. (VVOS)

NCM · Medical Devices

$0.42+0.02 (+4.22%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$5.8M
P/E (TTM)
EPS
$-2.23
Div Yield
52W Range
$0.36–$5.69
Beta
6.12

Company overview

Next earnings: 2026-08-14(17d)

Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.

Peers in Medical Devices

All in industry →

Recent press releases

Vivos Therapeutics, Inc. has not issued a press release in this window.

SEC filings

All filings →

Vivos Therapeutics, Inc. has not filed an SEC document in this window.

Vivos Therapeutics, Inc. has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
304,161 sh+232.6%
115,907 sh+179.5%
4 sh-100.0%
56,287 sh+5.6%
43,531 sh0.0%
14,776 sh● NEW
27,817 sh0.0%

People at Vivos Therapeutics, Inc.

All people →

Quarterly financials

Full financials →
Revenue trend
03/25
$1.2M
NI -$3.9M
06/25
$844.0K
NI -$5.0M
09/25
$6.8M
NI -$5.4M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $-0.49
Prior: $-0.55
Revenue sparkline